euclises.png
 

Euclises

Argonautic iSelect Special Situations Fund I SP (AISS)

Euclises is a drug discovery and development technology platform designed to offer novel pain and cancer medications. The company's platform focuses on developing novel cyclooxygenase-2 (COX-2) inhibitors for use in the oncology setting, as well as develops a portfolio of COX-2 inhibitors optimized for cancer treatment based on its proprietary Euclicoxib platform, enabling physicians to access advanced new molecules in combinations with both immune checkpoint and EGFR inhibitors to treat cancer.

VISIT WEBSITE